Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Chairperson and CEO Martine Rothblatt reported a mix of option exercises and stock sales. On March 3, 2026, she exercised 9,500 stock options, receiving an equal number of common shares, then sold 9,500 common shares in multiple open-market transactions.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. After the reported sales, she directly held 130 common shares, in addition to indirect holdings through her spouse and family trusts.
Morgan Stanley Smith Barney LLC files Form 144 to sell common shares of UTHR via stock option exercises. The notice lists multiple proposed sales dated 03/05/2026 and earlier, with individual transactions showing share quantities (8,300 and 11,000) and aggregate proceeds listed per trade.
United Therapeutics Corporation submitted a Form 144 notice of proposed sale of securities by an insider. The filing lists a planned stock option exercise and proposed sale of 20 common shares on 03/04/2026 for cash to the issuer. The filing also discloses three recent open-market sales by Christopher Causey: $520,000 for 1,000 shares on 02/25/2026, $510,000 for 1,000 shares on 01/06/2026, and $500,014.60 for 1,000 shares on 01/02/2026.
United Therapeutics reported a Form 144 notice proposing the sale of 2,000 common shares. The filing lists the proposed sale date as 03/04/2026, arising from a stock option exercise with proceeds to be received in cash. The record shows a prior sale of 910 shares on 12/18/2025 for $455,533.17.
United Therapeutics Corp director Jan Malcolm reported an open-market sale of 50 shares of common stock on March 3, 2026 at a price of $509.20 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following this sale, Malcolm beneficially owned 170 shares of common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported a series of insider trades in the company’s common stock. On March 2, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share, receiving 9,500 shares of common stock.
That same day, she conducted multiple open‑market sales totaling 9,500 shares of common stock, at reported weighted‑average prices generally between about $507 and $525 per share across numerous trades. The Form 4 notes these transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026.
The filing also reports indirect holdings of common stock through a spouse and various family trusts, where the reporting person or her immediate family share or hold investment power and are beneficiaries.
Morgan Stanley Smith Barney LLC Executive Financial Services reported a proposed sale of 50 shares of common stock (restricted stock) of United Therapeutics Corporation (symbol UTHR) under Form 144.
The filing lists multiple recent small dispositions of 50 shares each on 12/11/2025, 12/23/2025, 01/06/2026, 01/20/2026, 02/03/2026, and 02/17/2026, with per‑trade amounts shown in the excerpt.
Martine Rothblatt filed a Form 144 notice to sell 209,000 common shares of UTHR on 03/02/2026 via exercise of stock options through Morgan Stanley Smith Barney LLC, with payment in cash. The filing also lists multiple prior open-market dispositions in December 2025, mostly 4,000-share lots and one 2,000 lot.
UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of common stock. She sold 200 shares on February 27, 2026 at an average price of $509.55 per share under a pre-arranged Rule 10b5-1 trading plan entered into on November 24, 2025. After this transaction, she directly owns 4,845 common shares.